Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Bridion er større end risiciene til ophævelse af neuromuskulær blokade fremkaldt af rocuronium eller vecuronium.
The Committee for Medicinal Products for Human Use (CHMP) decided that Bridion’ s benefits are greater than its risks for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.